AP Biosciences Inc (TPEX:6945)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
116.00
-10.50 (-8.30%)
Aug 12, 2025, 1:00 PM CST
-8.30%
Market Cap10.77B
Revenue (ttm)n/a
Net Income (ttm)-422.75M
Shares Out85.11M
EPS (ttm)-5.61
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3
Average Volume764,495
Open126.00
Previous Close126.50
Day's Range116.00 - 127.00
52-Week Range36.30 - 178.00
Beta0.74
RSI70.34
Earnings DateAug 8, 2025

About Paramount Global

AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast ca... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 37
Stock Exchange Taipei Exchange
Ticker Symbol 6945
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.